ProCE Banner Activity

How I Manage My Patients With Myelodysplastic Syndrome

Clinical Thought
In this commentary, Daniel A. Pollyea, MD, MS, provides his strategies for treating patients with myelodysplastic syndrome.

Released: September 24, 2021

Expiration: September 23, 2022

No longer available for credit.

Share

Faculty

Daniel A. Pollyea

Daniel A. Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

Gilead Sciences, Inc.

Novartis Pharmaceuticals Corporation

Taiho Oncology Inc

Faculty Disclosure

Primary Author

Daniel A. Pollyea, MD, MS

Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Daniel A. Pollyea, MD, MS, has disclosed that he has received consulting fees from AbbVie, Aprea, Astellas, Bristol-Myers Squibb, Celgene, Foghorn, Genentech, Gilead Sciences, Kiadis, Novartis, Syndax, Syros, and Takeda Oncology and funds for research support from AbbVie and Teva.